On April 3, 2024, #XOMA completed its acquisition of #Kinnate Biopharma.? Kinnate’s #stockholders received $2.5879 cash per share and a #CVR for between 85% and 100% of the net proceeds associated with the license or sale of Kinnate’s programs.? More information can be found here https://bit.ly/4cJBrki.? We invite you to follow XOMA Royalty on LinkedIn at https://bit.ly/4cKGalS.?
Kinnate Biopharma Inc.
生物技术研究
San Diego，California 4,794 位关注者
Inspiring Hope to Those Battling Cancer
关于我们
Kinnate Biopharma Inc. is a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing medicines for known oncogenic drivers where there are no approved targeted drugs and to overcome the limitations, such as non-responsiveness or acquired and intrinsic resistance. Kinnate has two clinical programs being studied in solid tumors with RAF, NRAS and FGFR-driven alterations, and is rapidly progressing a pipeline of additional small molecule drug candidates as part of the Kinnate Discovery Engine. The company is driven by the urgency and knowledge that patients are waiting for new, effective cancer medicines.
- 网站
-
https://www.kinnate.com
Kinnate Biopharma Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- San Diego，California
- 类型
- 上市公司
- 创立
- 2018
- 领域
- Biotechnology、Cancer、Oncology、Precision Medicine、Precision Oncology和Drug Discovery
地点
Kinnate Biopharma Inc.员工
-
Barbara Warren
Vice President People and Culture
-
Michael Casarella
Experienced Leader in Biopharmaceutical Oncology- Medical Affairs and Global Thought Leader Engagement
-
Morgan Boren
Associate Director Toxicology Operations Nonclinical Development
-
Michael Rome
Managing Director & Head of Therapeutics Investing at Foresite Capital